Cellid Co., Ltd.

299660KOSDAQResearch and development

Cellid Co., Ltd. (299660, KOSDAQ) reported KRW 9bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
2023-126440Separate
20244-127651Separate
20259-1211174Separate

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
202363.4%-28.7%
2024-294.3%67.3%-23.9%
2025-136.5%66.9%-16.3%

Revenue moved 112.3% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 69bn
Close priceKRW 2,345
Listed shares29,502,977
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)49
Women25 (51%)
Average tenure3.2 years
Annual pay, menKRW 55,016,000
Annual pay, womenKRW 44,538,000
Pay ratio, women to men81%

Other companies in Research and development

63 listed companies file under this classification. Showing 12.

See the whole Research and development list →